LNTH

ANALYST NOTE: LANTHEUS HOLDINGS, INC. (LNTH) Date: June 13, 2026 Event Date: 2026-06-13

1. Structural Readiness

• State: Context-Only (No technical structure defined in source data)
• Conservative Entry: —
• Current Price: $103.86
• Extension: —
• ATR at Breakout: —
• ATR Current: 3.3% (Productive)
• Pivot Strength: —
• Cap Bucket: Mid
• Sector: Healthcare
• Industry: —

Structural Assessment:

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Diagnostics (Tier Direct, High Confidence).
• Thesis Weighting: The company is a direct beneficiary of the secular shift toward precision imaging in oncology and neurology. The thesis is reinforced by the "Quality Compounder" archetype, suggesting the business model is designed to compound value through recurring diagnostic utilization and pipeline expansion rather than one-off event speculation.
• Exposure Analysis: LNTH is positioned at the intersection of two high-growth diagnostic vectors: Prostate Cancer (PSMA) and Alzheimer's Disease (Amyloid). The directness of the exposure is high, as the company's core revenue drivers (PYLARIFY and NEUROCEQ) are the primary agents enabling the clinical guidelines and treatment pathways (DMTs) mentioned in the evidence.

3. Business Overview

Lantheus Holdings, Inc. is a global pharmaceutical company focused on the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. As of June 2026, the company has executed a strategic pivot to a pure-play nuclear medicine and diagnostic portfolio.

Key Business Activities & Evidence:

• Portfolio Composition: The company's product revenue is driven by PYLARIFY (PSMA PET imaging), NEUROCEQ (beta-amyloid PET imaging for Alzheimer's), DEFINITY (cardiac ultrasound contrast), and AZEDRA (therapeutic).
• *Evidence:* [E8] confirms product revenue includes PYLARIFY, Neuraceq, DEFINITY, and prior to Jan 1, 2026, TechneLite.
• *Evidence:* [E26] notes the therapeutic portfolio includes AZEDRA and RELISTOR.
• Strategic Divestiture: On January 1, 2026, the company completed the sale of its SPECT business to SHINE SPECT.
• *Evidence:* [E9] and [E10] detail the disposition, recognizing a net gain of $59.3 million. This transaction removed lower-margin or non-core assets, streamlining the balance sheet.
• Financial Performance (Q1 2026):
• *Evidence:* [E13] reports Q1 2026 product revenue of $369.8 million (up from $366.9 million in the prior period) and total revenues of $377.3 million.
• *Evidence:* [E5] notes PYLARIFY U.S. volume increased 5.8% year-over-year.
• *Evidence:* [E6] reports NEUROCEQ generated $35.4 million in Q1 2026, representing 14.3% sequential growth.
• Regulatory Milestones:
• *Evidence:* [E1] confirms the FDA approved PYLARIFY TRUVU (a new PSMA PET imaging agent) on March 6, 2026.
• *Evidence:* [E15] and [E16] reference the successful NDA submission and PDUFA date for the new F-18 PSMA formulation (Aphelion subsidiary), which was accepted in August 2025.
• Manufacturing & Supply:
• *Evidence:* [E3] states that over 70% of PYLARIFY supply is produced at PMF sites equipped with high-energy cycle times.
• *Evidence:* [E2] indicates management plans to begin a conversion process in Q4 2026.
• Capital Structure:
• *Evidence:* [E11] details an amendment to the revolving credit facility, increasing capacity to $750 million and extending maturity to December 2029.
• *Evidence:* [E12] notes a $400 million share repurchase program authorized in July 2025, running through December 2027.

4. Archetype and Conviction

• Archetype: Quality Compounder.
• Rationale: The company fits the "Quality Compounder" profile due to its recurring revenue model in diagnostics, strong cash flow generation (evidenced by the ability to fund a $400M buyback and a $750M credit facility), and successful execution of a strategic divestiture to focus on high-growth assets. The business is not a speculative biotech play but a commercial-stage entity with multiple revenue pillars.
• Valuation Context:
• *Evidence:* [E29] provides forward consensus EPS of $5.35 for FY1 and $6.38 for FY2.
• *Analysis:* At a current price of $103.86, the stock trades at approximately 19.4x FY1 consensus and 16.3x FY2 consensus. This valuation implies the market is pricing in continued growth but is not at extreme expansion multiples.
• Conviction Stack:
• Thesis Strength: High. The secular tailwinds in prostate and Alzheimer's diagnostics are structural and supported by clinical guidelines.
• Evidence Quality: High. The evidence base is robust, containing specific earnings transcripts, SEC filings, and financial data from the relevant period.
• Structural Quality: Moderate (Technical). While the business fundamentals are strong, the technical setup is undefined (context-only).
• Rerating Potential: Moderate to High. The combination of the new PYLARIFY TRUVU approval, the successful SPECT divestiture, and the NEUROCEQ growth trajectory provides multiple catalysts for multiple expansion, provided the technical structure can be established.

5. Invalidations, Strengtheners, and Gaps

• Invalidation Factors:
• Failure to execute the Q4 2026 conversion plan mentioned in [E2] could signal operational friction.
• Significant deviation from the $1.4B–$1.45B full-year 2026 revenue guidance provided in [E4].
• Strengtheners:
• Confirmation of the PYLARIFY TRUVU commercial uptake in Q2 2026.
• Continued sequential growth in NEUROCEQ revenue beyond the 14.3% Q1 growth rate.
• Successful execution of the $400M share repurchase program.
• Gaps in Evidence:
• Margin Data: While revenue is provided, specific gross margin or operating margin figures for Q1 2026 are not explicitly detailed in the provided evidence, limiting a full profitability assessment.
• Competitive Landscape: No specific evidence regarding competitive pressures or pricing power changes in the PSMA or Amyloid markets is provided in the source text.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: FDA approval of PYLARIFY TRUVU on March 6, 2026; Q1 2026 NEUROCEQ revenue growth of 14.3% to $35.4 million; strategic divestiture of SPECT business generating $59.3M net gain; forward consensus EPS of $5.35 for FY1. Sizing hint: Position size should be calibrated to the lack of a defined technical entry; consider scaling in as a structural setup forms rather than a lump sum. Expected path: Management expects the conversion to begin in Q4 2026, with revenue guidance holding at $1.4B-$1.45B for the full year; the company is positioned to compound value through the new TRUVU agent and Alzheimer's market expansion. Expected horizon: 12 to 18 months for the full impact of the new product approvals and conversion to be reflected in earnings.